Home LiteratureArticle Details
PMID: 18060598 Published · ppublish English Clinical Trial, Phase I Clinical Trial, Phase II Journal Article

A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798).

Investigational new drugs ·Vol. 26 ·No. 2 ·2008-04-00 ·Pages 193-4

Knox JJ, Chen XE, Feld R, Nematollahi M, Cheiken R, Pond G, Zwiebel JA, Gill S, Moore M

Abstract

暂无摘要

MeSH Terms
Adult Aged Antineoplastic Combined Chemotherapy Protocols/adverse effects,therapeutic use Carcinoma, Hepatocellular/drug therapy Dose-Response Relationship, Drug Doxorubicin/administration & dosage Female Hematologic Diseases/chemically induced Humans Liver Neoplasms/drug therapy Male Middle Aged Proto-Oncogene Proteins c-bcl-2/metabolism Thionucleotides/administration & dosage Treatment Outcome
Chemicals
Proto-Oncogene Proteins c-bcl-2 Thionucleotides Doxorubicin oblimersen
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Knox J J
Princess Margaret Hospital Phase II Consortium, and University Health Network, University of Toronto, Toronto, Ontario, Canada. [email protected]
Chen X E
Feld R
Nematollahi M
Cheiken R
Pond G
Zwiebel J A
Gill S
Moore M
References (11)
11 references, click to expand
  1. Apoptosis in diseases of the liver.
    Crit Rev Clin Lab Sci. 2001 Apr;38(2):109-66 PMID: 11347718
  2. Chemosensitivity of human hepatocellular carcinoma cell line QGY-7703 is related to bcl-2 protein levels.
    Tumour Biol. 1999 Nov-Dec;20(6):331-40 PMID: 10567879
  3. Apoptosis in liver diseases--detection and therapeutic applications.
    Med Sci Monit. 2005 Nov;11(11):RA337-45 PMID: 16258409
  4. Primary liver cancer. An Eastern Cooperative Oncology Group Trial.
    Cancer. 1984 Sep 15;54(6):970-7 PMID: 6088019
  5. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death.
    Semin Cancer Biol. 1993 Dec;4(6):327-32 PMID: 8142617
  6. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
    Oncogene. 2008 Mar 13;27(12):1749-58 PMID: 17891174
  7. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial.
    Cancer. 1988 Aug 1;62(3):479-83 PMID: 2839280
  8. Taxol induced Bcl-2 protein phosphorylation in human hepatocellular carcinoma QGY-7703 cell line.
    Cell Biol Int. 2001;25(3):261-5 PMID: 11352500
  9. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Clin Cancer Res. 2000 Jul;6(7):2891-902 PMID: 10914739
  10. Induction of remission in hepatocellular carcinoma with doxorubicin.
    Lancet. 1978 May 13;1(8072):1006-9 PMID: 76932
  11. Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocellular carcinoma.
    Dig Dis Sci. 2003 Apr;48(4):670-6 PMID: 12741454
Article Info
Journal
Investigational new drugs
Abbr.
Invest New Drugs
ISSN
0167-6997
DOI
10.1007/s10637-007-9104-1
Email
[email protected]
Published
2008-04-00
Epub
2007-00-04
Pages
193-4
Language
English
Region
United States
NLM ID
8309330
Subset
IM
External Links
PubMed source DOI: 10.1007/s10637-007-9104-1 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2